Trial Profile
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients With Symptomatic Gastroesophageal Reflux Disease Not Completely Responsive to Proton Pump Inhibitors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2020
Price :
$35
*
At a glance
- Drugs Colesevelam (Primary)
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- Sponsors Ironwood Pharmaceuticals
- 26 Feb 2020 According to an Ironwood Pharmaceuticals media release, data from this study was published in the Gastroenterology - the official journal of the American Gastroenterological Association (AGA).
- 26 Feb 2020 Results published in the Ironwood Pharmaceuticals Media Release
- 12 Feb 2020 Results assessing efficacy and safety of IW-3718 as an adjunct to PPI therapy in refractory gastroesophageal reflux disease, published in the Gastroenterology.